Latest Share News for Moderna Inc
Read all the latest Moderna Inc USD0.0001 share news, regulatory announcements and tips.
www.hl.co.ukHere’s the latest on Moderna stock (MRNA) based on recent reporting up to May 2026.
Direct answer
- Moderna has been in focus due to quarterly results, pipeline progress, and guidance for 2026, with investors watching both COVID-19 vaccine demand and growth in its broader mRNA portfolio.
Key recent themes
- Financial updates: In late 2025/early 2026 reporting cycles, Moderna outlined 2025 sales near or around the upper end of prior guidance, and provided 2026 revenue and operating expense expectations tied to its COVID vaccine franchise and expanded pipeline.[1][2]
- Pipeline and partnerships: The company continued advancing its multi-program mRNA portfolio across infectious disease, oncology, and rare diseases, with milestones expected across 2026 and beyond; investors remain attentive to any progress on combinations or new vaccine applications.[6][1]
- Stock movement and sentiment: Moderna’s shares have experienced periods of volatility tied to quarterly results, guidance updates, and broader biotech/biopharma market dynamics; media coverage and analyst notes in early 2026 reflect a cautious-but-optimistic stance pending meaningful pipeline milestones and cash-flow trajectory.[10][1]
What to watch next
- 2026 revenue guidance updates: Any revisions to expectations for COVID vaccine demand and non-COVID programs.
- Cash flow and profitability milestones: Updates on cash burn, operating expenses, and potential path to cash flow breakeven.
- Pipeline milestones: Readouts from key clinical trials, especially any data on mRNA-1010-related programs or new vaccine/therapeutic candidates.
- Regulatory updates: Any FDA feedback or new regulatory approvals/denials affecting pipeline candidates.
If you’d like, I can pull the most current headlines and summarize the top three to five stories, or build a quick chart of Moderna’s recent stock moves with dates and headline drivers. I can also set up a concise watchlist with key data points (market cap, YTD change, and latest guidance) if you plan to monitor MRNA closely.